The pharmaceutical industry of Europe for tariffs as hopes are fading

Copenhagen, Denmark-the pharmaceutical sector of Europe is preparing for the potential impact of US tariffs such as the hope of an exemption from the entire industry by the president of the United States, Donald Trump, Fade.

The pharmaceutical industry has been exempt from commercial taxes, but Trump confirmed last week that he would soon impose tariffs on the sector.

The drug manufacturers are now pressing the president for a gradual approach to tariffs on imports to the United States, Reuters reported Tuesday, citing four sources familiar with discussions. The sources said the taxes may not be announced on Wednesday, but they were probably inevitable.

The gradual implementation of tariffs on the sector could reduce the immediate financial coup and allow companies to relocate their United States in the United States. However, some companies have warned that lack of clarity is already having negative side effects.

“For us, what is more important is not just the impact of tariffs, it is also the impact it has on the market,” Ester Baiget, CEO of the Danish firm of Biotechnology Novonesis, told CNBC on Tuesday.

“When you bring rates, it drives uncertainty and when [are] Uncertain, pause, stops innovation, publishes launches, stops investments, “said Baiget, whose signature derives around 30% of the US sales. But also increased its presence of manufacturing in the country.

Denmark is one of the largest pharmaceutical and biotechnology centers in Europe, home of companies, including the couples manufacturer, Novo Nordisk and the Bavarian Nordic vaccine producer, which have high exposure to the United States

The president of Novo Nordisk told CNBC last week that the company was not speculating ahead of Trump's rates ad and, instead, he focused on staying flexible.

“It doesn't make much sense to speculate too much,” President Helge Lund told CNBC out of the annual general meeting of the Danish pharmaceutical giant. “We are focused on the laser on what we can affect.”

Even so, questions have been asked about how tariffs could affect US sales of obesity treatments and greatly popular Diabetes of Novo, and the implications for the rival and the manufacturer of Zepbound of the United States. Eli Lilly. Lund would not be pressed on the part of its sales of weight loss derived from US plants, but point to the “very significant” manufacturing configuration of the company in the US.

The threat of tariffs has also joined uncertainty within the investment panorama. In statements to CNBC on Monday, Emily Field, head of research of European pharmaceutical products in Barclays, cited tariffs such as “Question number 1 in the minds of investors.”

Morten Bødskov, the Minister of Industry, Business and Financial Affairs of Denmark, told CNBC on Tuesday that he was in contact with the pharmaceutical industry and the country's corporations on the potential impact of tariffs on the small export economy.

“We are, of course, in a close dialogue with them,” said Bødskov. “Our work is to bring them to discussions about the way the world is changing. Many of them are leading companies in the world, so it is our work to help them see the prospects of future markets,” he added.

However, he pointed out that it was not clear if the Trump administration could be persuaded to revert its protectionist policies or take into account certain sectors.

Meanwhile, for companies such as novonesis, Baiget said it was a matter of seeing the events “very close”, and preparing for action if necessary.

“There is a lot of volatility, and there are many rapid movement trends,” he said. “It is important that we decoupling, and we also learn how to cushion some of them.”